Clinitech Laboratory profit falls 19% despite revenue growth

Clinitech Laboratory Limited reported standalone profit after tax of Rs 24.46 lakh for the half year ended September 30, 2026, down 19% from Rs 30.03 lakh a year earlier, even as revenue from operations rose 8% to Rs 5.49 crore. Higher expenses and tax expense reduced the bottom-line outcome.

Why did Clinitech Laboratory's profit decline despite higher revenue?

Clinitech Laboratory's standalone profit after tax fell because total expenses rose slightly more than total income in the half year ended September 30, 2026, while tax expense increased. Total income increased to Rs 5.52 crore from Rs 5.19 crore in the half year ended September 30, 2025, but total expenses rose to Rs 5.17 crore from Rs 4.84 crore.

The increase in total income was Rs 32.80 lakh, compared with a Rs 32.89 lakh increase in total expenses. As a result, profit before tax was broadly unchanged at Rs 34.99 lakh, against Rs 35.08 lakh a year earlier. The movement indicates that the revenue gain did not translate into a higher pre-tax profit during the September 2026 half year.

Total tax expense increased to Rs 10.53 lakh from Rs 5.05 lakh in the corresponding 2025 half year. Current tax was Rs 9.57 lakh and deferred tax was Rs 0.95 lakh in the September 2026 period. After this tax charge, profit after tax was Rs 24.46 lakh, down Rs 5.57 lakh from Rs 30.03 lakh.

Which costs increased in Clinitech Laboratory's standalone results?

Clinitech Laboratory recorded its largest disclosed expense increase in other expenses, which rose to Rs 1.80 crore in the half year ended September 30, 2026 from Rs 1.42 crore a year earlier. The Rs 38.07 lakh increase exceeded the Rs 32.80 lakh rise in total income for the same comparison.

Employee benefits expense rose by Rs 8.64 lakh to Rs 1.66 crore, while depreciation and amortisation increased by Rs 5.02 lakh to Rs 30.07 lakh. These increases were partly offset by lower consumables costs, which fell by Rs 15.70 lakh to Rs 1.22 crore, and laboratory testing charges, which declined by Rs 1.39 lakh to Rs 16.04 lakh.

Finance costs fell to Rs 2.99 lakh from Rs 4.74 lakh in the year-earlier half. Nevertheless, the combined rise in other expenses, employee benefits and depreciation left total expenses at Rs 5.17 crore. The filing does not provide a further breakdown explaining the increase in other expenses.

How did Clinitech Laboratory's September 2026 half compare sequentially?

Clinitech Laboratory's revenue from operations increased to Rs 5.49 crore in the half year ended September 30, 2026 from Rs 4.39 crore in the half year ended March 31, 2026. Profit after tax also rose to Rs 24.46 lakh from Rs 12.23 lakh in the preceding half year.

Profit before tax rose to Rs 34.99 lakh from Rs 25.31 lakh between the two half-year periods. Total income increased by Rs 1.05 crore to Rs 5.52 crore, while total expenses increased by Rs 94.85 lakh to Rs 5.17 crore. The sequential profit increase therefore differed from the year-on-year decline against the September 2025 half year.

The March 2026 half-year tax expense was Rs 13.08 lakh, including Rs 5.17 lakh classified as excess or short provision of income tax. In the September 2026 half year, total tax expense was Rs 10.53 lakh. Basic and diluted earnings per share were Rs 1.07 for September 2026, compared with Rs 0.59 for March 2026 and Rs 1.32 for September 2025.

How did Clinitech Laboratory's balance sheet change?

Clinitech Laboratory's standalone total assets increased to Rs 11.94 crore at September 30, 2026 from Rs 10.91 crore at March 31, 2026. Property, plant and equipment increased by Rs 53.27 lakh to Rs 2.68 crore, while trade receivables rose by Rs 40.42 lakh to Rs 2.25 crore.

Other current assets increased by Rs 20.89 lakh to Rs 2.24 crore, and inventories rose by Rs 3.32 lakh to Rs 76.37 lakh. Cash and cash equivalents declined by Rs 19.26 lakh to Rs 1.87 crore. Despite the cash reduction, total current assets increased to Rs 7.78 crore from Rs 7.36 crore at the March 2026 year end.

Long-term borrowings increased to Rs 86.44 lakh at September 30, 2026 from Rs 35.76 lakh six months earlier. Share capital was unchanged at Rs 2.28 crore, while reserves and surplus increased by Rs 24.47 lakh to Rs 7.22 crore. Total equity and liabilities rose to Rs 11.94 crore from Rs 10.91 crore, matching total assets.

How did Clinitech Laboratory fund capital spending and working capital?

Clinitech Laboratory generated net cash from operating activities of Rs 13.71 lakh in the half year ended September 30, 2026. Cash generated from operations before income taxes was Rs 23.29 lakh, after a Rs 40.42 lakh cash outflow related to higher trade receivables and a Rs 20.90 lakh outflow related to other assets.

Working-capital uses were partly offset by a Rs 14.39 lakh increase in trade payables, a Rs 9.05 lakh increase in short-term provisions and a Rs 4.02 lakh increase in other liabilities. Income taxes paid were Rs 9.58 lakh, reducing the operating cash inflow to Rs 13.71 lakh for the six-month period.

Investing activities used Rs 81.80 lakh, including Rs 82.36 lakh spent on property, plant, equipment and intangible assets. Financing activities provided Rs 48.82 lakh, comprising Rs 50.67 lakh in proceeds from long-term borrowings less Rs 1.85 lakh in interest paid. These movements resulted in a Rs 19.26 lakh decline in cash and cash equivalents to Rs 1.87 crore.

What does Clinitech Laboratory disclose about its business and financial review?

Clinitech Laboratory says it operates in one segment, pathology and healthcare, so segment-wise reporting under Accounting Standard 17 is not applicable. The September 2026 standalone results were prepared under applicable Accounting Standards rather than Indian Accounting Standards, because the filing says SME Exchange-listed companies are exempt from mandatory adoption under the cited Ministry of Corporate Affairs notification.

The Audit Committee reviewed the unaudited results and the board took them on record on November 13, 2026. Kale Malde & Co. issued a limited review report dated November 13, 2026, stating that nothing had come to its attention to suggest the standalone results failed to make required disclosures or contained a material misstatement.

The auditor also stated that a limited review is substantially less extensive than an audit and does not express an audit opinion. Clinitech Laboratory reported revenue, expense, balance-sheet and cash-flow information on a standalone basis, while the board announcement also approved consolidated results for the half year ended September 30, 2026.

Conclusion

Clinitech Laboratory delivered 8% year-on-year growth in standalone revenue for the half year ended September 30, 2026, but a Rs 38.07 lakh increase in other expenses and a higher tax charge left profit after tax 19% lower at Rs 24.46 lakh. The balance sheet also showed higher receivables, fixed assets and long-term borrowings over the six-month period.

The unresolved matters disclosed by the filing are whether trade receivables of Rs 2.25 crore convert into operating cash and how the Rs 82.36 lakh spent on property, plant, equipment and intangible assets affects subsequent operations. Clinitech Laboratory did not disclose a revenue target, capital-expenditure plan, earnings guidance or a scheduled next-results date in the supplied announcement.